Alberca I, Hermida J (April 2006). "The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated
it occurs in far smaller quantities in other plant tissues. Detection of VKORC1 homologues active on the K1-epioxide suggest that K1 may have a non-redox
Keutel syndrome, deficiency of vitamin K epoxide reductase subunit 1 (VKORC1), gamma-glutamyl carboxylase (GGCX), Xp contiguous deletion syndromes, and
drugs. However, with the discovery of polymorphic variants in CYP2C9 and VKORC1 genotypes, two genes that encode the individual anticoagulant response,
pharmacogenetics of adverse drug reactions and drug efficacy. His team identified VKORC1 gene variants to play a major role in determining the warfarin dosage, a
Kenneth E.; Veenstra, David L.; Rettie, Allan E. (June 2, 2005). "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose". The New England
arteriosclerosis. Specific genetic mutations in the cardiovascular related genes VKORC1, NT5E, and ABCC6 have a potential role in the development of the disease
Wadelius M, Deloukas P (March 2009). "A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose"
vitamin K reductase (VKOR) enzyme. Sequencing of the associated VKOR gene, VKORC1, in rat and mice species indicated mutations in said gene. There was also
L, Kornreich, R and Desnick, RJ: Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotype predict different sensitivities and resistance frequencies in the